These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 2630251

  • 1. Antiresorptive dose-response relationships across three generations of bisphosphonates.
    Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA.
    Drugs Exp Clin Res; 1989; 15(9):389-96. PubMed ID: 2630251
    [Abstract] [Full Text] [Related]

  • 2. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
    Rogers MJ, Xiong X, Brown RJ, Watts DJ, Russell RG, Bayless AV, Ebetino FH.
    Mol Pharmacol; 1995 Feb; 47(2):398-402. PubMed ID: 7870050
    [Abstract] [Full Text] [Related]

  • 3. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG.
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 6. Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats.
    Astrand J, Aspenberg P.
    Acta Orthop Scand; 2002 Jan; 73(1):24-30. PubMed ID: 11928907
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonates: structure-activity relations from a clinical perspective.
    Papapoulos SE.
    Medicina (B Aires); 1997 Jan; 57 Suppl 1():61-4. PubMed ID: 9567357
    [Abstract] [Full Text] [Related]

  • 8. Short- and long-term effects of a single dose of bisphosphonates on retinoid-induced bone resorption in thyroparathyroidectomized rats.
    Stutzer A, Fleisch H, Trechsel U.
    Calcif Tissue Int; 1988 Nov; 43(5):294-9. PubMed ID: 3145796
    [Abstract] [Full Text] [Related]

  • 9. Effect of a single injection of two new bisphosphonates on the hypercalcemia and hypercalciuria induced by Walker carcinosarcoma 256/B in thyroparathyroidectomized rats.
    Kozak S, Rizzoli R, Trechsel U, Fleisch H.
    Cancer Res; 1987 Dec 01; 47(23):6193-7. PubMed ID: 3677071
    [Abstract] [Full Text] [Related]

  • 10. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.
    Van Beek E, Löwik C, Que I, Papapoulos S.
    J Bone Miner Res; 1996 Oct 01; 11(10):1492-7. PubMed ID: 8889849
    [Abstract] [Full Text] [Related]

  • 11. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P.
    Basic Clin Pharmacol Toxicol; 2005 Dec 01; 97(6):382-91. PubMed ID: 16364054
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of action of the bisphosphonates.
    Fleisch H.
    Medicina (B Aires); 1997 Dec 01; 57 Suppl 1():65-75. PubMed ID: 9567358
    [Abstract] [Full Text] [Related]

  • 13. Hypercalcemia induced with an arotinoid in thyroparathyroidectomized rats. New model to study bone resorption in vivo.
    Trechsel U, Stutzer A, Fleisch H.
    J Clin Invest; 1987 Dec 01; 80(6):1679-86. PubMed ID: 3680521
    [Abstract] [Full Text] [Related]

  • 14. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
    Kotsikorou E, Oldfield E.
    J Med Chem; 2003 Jul 03; 46(14):2932-44. PubMed ID: 12825934
    [Abstract] [Full Text] [Related]

  • 15. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
    Moran EL, Fornasier TL, Bogoch TR.
    J Orthop Res; 2000 Nov 03; 18(6):873-81. PubMed ID: 11192246
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.
    Clézardin P, Ebetino FH, Fournier PG.
    Cancer Res; 2005 Jun 15; 65(12):4971-4. PubMed ID: 15958534
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
    Flanagan AM, Chambers TJ.
    Calcif Tissue Int; 1991 Dec 15; 49(6):407-15. PubMed ID: 1840176
    [Abstract] [Full Text] [Related]

  • 18. Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment: application to the study of intravenous 14C-labeled 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate.
    Koopmans SJ, van der Wee-Pals L, Löwik CW, Papapoulos SE.
    J Bone Miner Res; 1994 Feb 15; 9(2):241-6. PubMed ID: 8140937
    [Abstract] [Full Text] [Related]

  • 19. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
    Hodsman A, Adachi J, Olszynski W.
    CMAJ; 1996 Oct 01; 155(7):945-8. PubMed ID: 8837544
    [Abstract] [Full Text] [Related]

  • 20. [Preclinical toxicology of bisphosphonates].
    Mondelo N, Peluffo VA, Parma MD, Cointry GR, Capozza RF, Ferretti JL, Piccinni E, Montuori E.
    Medicina (B Aires); 1997 Oct 01; 57 Suppl 1():93-100. PubMed ID: 9567361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.